Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.

Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.

Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza...

Full description

Bibliographic Details
Main Authors: Maki Kiso, Shuku Kubo, Makoto Ozawa, Quynh Mai Le, Chairul A Nidom, Makoto Yamashita, Yoshihiro Kawaoka
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-02-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC2829070?pdf=render

Similar Items

Similar Items